scholarly journals Severity of COVID-19 Infection in ACEI/ARB Users in Specialty Hospitals: A Retrospective Cohort Study

2021 ◽  
Author(s):  
Ahmed A. Alrashed ◽  
Tahir M. Khan ◽  
Noara K. Alhusseini ◽  
Syed Mohammed Basheeruddin Asdaq ◽  
Mushira Enani ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Specialty Hospitals

scholarly journals Severity of COVID-19 Infection in ACEI/ARB Users in Two Saudi Public Specialty Hospitals; Retrospective Cohort Study

2020 ◽  
Author(s):  
Ahmed A. Alrashed ◽  
Tahir M. Khan ◽  
Noara K. Alhusseini ◽  
Syed Mohammed Basheeruddin Asdaq ◽  
Mushira Enani ◽  
...  
Keyword(s):  
Cohort Study ◽  
Renal Disease ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Enzyme Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme Inhibitors ◽  
Specialty Hospitals ◽  
Patients With Diabetes

Abstract The uncertainty about COVID-19 outcomes in angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) users continues with contradictory findings. The aim of this study was to determine the effect of ACEI/ARB use in patients with severe COVID-19. This retrospective cohort study done in two Saudi public specialty hospitals designated as COVID-19 referral facilities. We included 354 patients with confirmed diagnosis of COVID-19 between April and June 2020, of which 146 were ACEI/ARB users and 208 were non-ACEI/ARB users. Controlling for confounders, we conducted a multivariate logistic regression and a sensitivity analysis using propensity score matched (PSM) patients. Compared to non-ACEI/ARB users, ACEI/ARB users had an eight-fold higher risk of developing critical or severe COVID-19 (OR=8.25, 95%CI=3.32-20.53); a nearly 7-fold higher risk of intensive care unit (ICU) admission (OR=6.76, 95%CI=2.88-15.89) and a nearly 5-fold higher risk of requiring noninvasive ventilation (OR=4.77,95%CI=2.15-10.55). Patients with diabetes, hypertension, and/or renal disease had a five-fold higher risk of severe COVID-19 disease (OR=5.40,95%CI=2.0-14.54]. These results were confirmed in the PSM analysis. In general, but especially among patients with hypertension, diabetes, and/or renal disease, ACEI/ARB use is associated with a significantly higher risk of severe or critical COVID-19 disease, and ICU care.

scholarly journals Severity of COVID-19 Infection in ACEI/ARB Users in Two Saudi Public Specialty Hospitals: Retrospective Cohort Study

2020 ◽  
Author(s):  
Ahmed A. Alrashed ◽  
Tahir Khan ◽  
Noara Alhusseini ◽  
Syed Mohammed Asdaq ◽  
Mushira Enani ◽  
...  
Keyword(s):  
Cohort Study ◽  
Propensity Score ◽  
Renal Disease ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Angiotensin Receptor Blockers ◽  
High Risk Patient ◽  
Sensitivity Analyses ◽  
Converting Enzyme Inhibitors ◽  
Specialty Hospitals

Abstract Background: The uncertainty about COVID-19 outcomes in angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) users continues with contradictory findings. The aim of this study was to determine the effect of ACEI/ARB use in patients with severe COVID-19. Methods: This retrospective cohort study was done in two Saudi public specialty hospitals designated as COVID-19 referral facilities. We included 354 patients with confirmed diagnosis of COVID-19 between April and June 2020, of which 146 were ACEI/ARB users and 208 were non-ACEI/ARB users. Controlling for confounders, we conducted a multivariate logistic regression and a sensitivity analyses using propensity score matching (PSM) and Inverse propensity score weighting (IPSW) for high risk patient subsets. Results: Compared to non-ACEI/ARB users, ACEI/ARB users had an eight-fold higher risk of developing critical or severe COVID-19 (OR=8.25, 95%CI=3.32-20.53); a nearly 7-fold higher risk of intensive care unit (ICU) admission (OR=6.76, 95%CI=2.88-15.89) and a nearly 5-fold higher risk of requiring noninvasive ventilation (OR=4.77,95%CI=2.15-10.55). Patients with diabetes, hypertension, and/or renal disease had a five-fold higher risk of severe COVID-19 disease (OR=5.40,95%CI=2.0-14.54]. These results were confirmed in the PSM and IPSW analyses. Conclusion: In general, but especially among patients with hypertension, diabetes, and/or renal disease, ACEI/ARB use is associated with a significantly higher risk of severe or critical COVID-19 disease, and ICU care.

Tu1788 CLINICAL CHARACTERISTICS AND TREATMENT DIFFERENCES BETWEEN YOUNGER AND OLDER ONSET MICROSCOPIC COLITIS: A MULTICENTER RETROSPECTIVE COHORT STUDY

2020 ◽  
Vol 158 (6) ◽  
pp. S-1161
Author(s):  
Amrit K. Kamboj ◽  
Amandeep Gujral ◽  
Elida Voth ◽  
Daniel Penrice ◽  
Jessica McGoldrick ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Clinical Characteristics ◽  
Microscopic Colitis

Early-Onset Thrombocytopenia in Small-for-Gestational-Age Neonates: A Retrospective Cohort Study

2016 ◽  
Vol 33 (S 01) ◽  
Author(s):  
S. Fustolo-Gunnink ◽  
R. Vlug ◽  
V. Smits-Wintjens ◽  
E. Heckman ◽  
A. Te Pas ◽  
...  
Keyword(s):  
Cohort Study ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Retrospective Cohort Study ◽  
Early Onset ◽  
Retrospective Cohort
Sign in / Sign up

Export Citation Format

Share Document